Notably, the therapeutic implication draws from the multifaceted role that PARs play in modulating gastrointestinal inflammation and metabolic homeostasis, further bolstering the case for PAR2-targeted treatments in dual-pathology contexts such as IBD with concurrent metabolic syndrome [127]. The gene discussed is F2RL1; the disease is metabolic syndrome.